AU2005243834A1 - Camptothecin derivatives conjugated in position 20 with integrin antagonists - Google Patents
Camptothecin derivatives conjugated in position 20 with integrin antagonists Download PDFInfo
- Publication number
- AU2005243834A1 AU2005243834A1 AU2005243834A AU2005243834A AU2005243834A1 AU 2005243834 A1 AU2005243834 A1 AU 2005243834A1 AU 2005243834 A AU2005243834 A AU 2005243834A AU 2005243834 A AU2005243834 A AU 2005243834A AU 2005243834 A1 AU2005243834 A1 AU 2005243834A1
- Authority
- AU
- Australia
- Prior art keywords
- group
- branched
- linear
- alkyl
- phe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITRM2004A000241 | 2004-05-13 | ||
| IT000241A ITRM20040241A1 (it) | 2004-05-13 | 2004-05-13 | Camptotecine coniugate in posizione 20 con antagonisti delle integrine. |
| PCT/IT2005/000261 WO2005110487A2 (en) | 2004-05-13 | 2005-05-04 | Camptothecin derivatives conjugated in position 20 with integrin antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2005243834A1 true AU2005243834A1 (en) | 2005-11-24 |
Family
ID=35124307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2005243834A Abandoned AU2005243834A1 (en) | 2004-05-13 | 2005-05-04 | Camptothecin derivatives conjugated in position 20 with integrin antagonists |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20070232639A1 (https=) |
| EP (1) | EP1747019A2 (https=) |
| JP (1) | JP2007537244A (https=) |
| CN (1) | CN101010103A (https=) |
| AR (1) | AR049275A1 (https=) |
| AU (1) | AU2005243834A1 (https=) |
| BR (1) | BRPI0511037A (https=) |
| CA (1) | CA2562572A1 (https=) |
| IT (1) | ITRM20040241A1 (https=) |
| MX (1) | MXPA06012886A (https=) |
| TW (1) | TW200538125A (https=) |
| WO (1) | WO2005110487A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2604284A1 (en) | 2007-02-16 | 2013-06-19 | KTB Tumorforschungsgesellschaft mbH | Receptor And Antigen Targeted Prodrug |
| BR112014016736A8 (pt) * | 2012-01-27 | 2017-07-04 | Hoffmann La Roche | composto, composição farmacêutica, método para tratamento, uso de um composto e invenção |
| CN105399757A (zh) * | 2015-12-29 | 2016-03-16 | 遵义医学院 | 酸敏感型喜树碱-20位去甲斑蝥酸酯衍生物及其抗肿瘤应用 |
| CN111068068A (zh) * | 2019-12-04 | 2020-04-28 | 云南民族大学 | 一种rgd多肽-喜树碱多肽药物偶联物及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19815812A1 (de) * | 1998-04-08 | 1999-10-14 | Bayer Ag | Modifizierte Cytostatika |
| ATE216998T1 (de) * | 1999-03-09 | 2002-05-15 | Sigma Tau Ind Farmaceuti | Camptothecin-derivate mit antitumor-wirkung |
| US6207832B1 (en) * | 1999-04-09 | 2001-03-27 | University Of Pittsburgh | Camptothecin analogs and methods of preparation thereof |
| DE60042700D1 (de) * | 1999-09-08 | 2009-09-17 | Markus Albers | Integrin-vermittelte arzneimittel-zielrichtung |
-
2004
- 2004-05-13 IT IT000241A patent/ITRM20040241A1/it unknown
-
2005
- 2005-05-04 TW TW094114403A patent/TW200538125A/zh unknown
- 2005-05-04 WO PCT/IT2005/000261 patent/WO2005110487A2/en not_active Ceased
- 2005-05-04 US US11/596,189 patent/US20070232639A1/en not_active Abandoned
- 2005-05-04 JP JP2007512735A patent/JP2007537244A/ja not_active Withdrawn
- 2005-05-04 MX MXPA06012886A patent/MXPA06012886A/es not_active Application Discontinuation
- 2005-05-04 EP EP05743015A patent/EP1747019A2/en not_active Withdrawn
- 2005-05-04 CA CA002562572A patent/CA2562572A1/en not_active Abandoned
- 2005-05-04 AU AU2005243834A patent/AU2005243834A1/en not_active Abandoned
- 2005-05-04 BR BRPI0511037-8A patent/BRPI0511037A/pt not_active IP Right Cessation
- 2005-05-04 CN CNA2005800152323A patent/CN101010103A/zh active Pending
- 2005-05-12 AR ARP050101933A patent/AR049275A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0511037A (pt) | 2007-11-27 |
| EP1747019A2 (en) | 2007-01-31 |
| ITRM20040241A1 (it) | 2004-08-13 |
| MXPA06012886A (es) | 2007-02-15 |
| WO2005110487A3 (en) | 2007-02-15 |
| TW200538125A (en) | 2005-12-01 |
| US20070232639A1 (en) | 2007-10-04 |
| JP2007537244A (ja) | 2007-12-20 |
| CA2562572A1 (en) | 2005-11-24 |
| WO2005110487A2 (en) | 2005-11-24 |
| AR049275A1 (es) | 2006-07-12 |
| CN101010103A (zh) | 2007-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3607201B2 (ja) | Fap活性化抗腫瘍性化合物 | |
| US9579317B2 (en) | Peptide-drug conjugates | |
| AU2005243417B2 (en) | Camptothecins conjugated in position 7 to cyclic peptides as cytostatic agents | |
| AU2005243834A1 (en) | Camptothecin derivatives conjugated in position 20 with integrin antagonists | |
| US7589099B2 (en) | 7-t-butoxyiminomethylcamptothecin conjugated in position 20 with integrin antagonists | |
| JP4127325B2 (ja) | ビオチン誘導体 | |
| EP1751176B1 (en) | Cyclopeptide derivatives with anti-integrin activity | |
| US20060205637A1 (en) | Fluoro-alkyl-cyclopeptide derivatives having anti-integrin activity | |
| HK1107005A (en) | Camptothecin derivatives conjugated in position 20 with integrin antagonists | |
| KR20070022290A (ko) | 인테그린 길항물질과 20 번 위치에서 공액된7-티-부톡시이미노메틸캄토테신 | |
| KR20070022292A (ko) | 인테그린 길항물질과 20 번 위치에서 공액된 캄토테신유도체 | |
| HK1104047A (en) | Camptothecins conjugated in position 7 to cyclic peptides as cytostatic agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |